2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009

Cannabis Science Inc. Chosen on StockProfile.com

Cannabis Science Inc. Chosen on StockProfile.com

COLORADO SPRINGS, Colo., (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS - News), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce today that they have expanded their market awareness program by joining www.StockProfile.com, a customized web-based platform showcasing emerging growth stocks.

StockProfile.com provides the investing public with a free unique information portal for investors who like to conduct their own research and make their own investment decisions. The platform allows users to review and investigate dynamic publicly traded companies in a user-friendly environment.

Cannabis Science is pleased to team up with StockProfile.com in providing independent minded investors seeking new growth companies for investment. The profile is listed at www.StockProfile.com and can be viewed by searching under the stock symbol CBIS.

Dr. Robert Melamede, PhD., Cannabis Science President and CEO, remarked, "In our continuing effort to increase shareholder value and to increase public awareness of our growing and dynamic company we are pleased to join StockProfile.com. This is another important step CBIS is taking to ensure that its shareholders and investment community have continued access to information about how we are building a patient oriented company, especially our efforts to bring badly needed FDA quality pharmaceutical cannabis to those who need it most, our veterans with PTSD and related problems. Public education is a very important part of our mission, so it is extremely exciting to be chosen by StockProfile.com and added to their impressive roster of growth companies."

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.